Apyx Medical Corporation
APYX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.27 | 0.00 | 0.23 |
| FCF Yield | 0.00% | -1.63% | -1.55% | -5.27% |
| EV / EBITDA | 24.68 | -46.87 | -18.55 | -24.29 |
| Quality | ||||
| ROIC | -1.85% | -5.43% | -6.05% | -5.70% |
| Gross Margin | 64.43% | 62.28% | 60.07% | 63.03% |
| Cash Conversion Ratio | 1.78 | 0.33 | 0.17 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.61% | -0.65% | 2.31% | 2.62% |
| Free Cash Flow Growth | -170.69% | -97.89% | 76.21% | 30.72% |
| Safety | ||||
| Net Debt / EBITDA | 24.68 | -4.52 | -2.59 | -2.53 |
| Interest Coverage | 0.59 | -1.85 | -2.22 | -1.84 |
| Efficiency | ||||
| Inventory Turnover | 0.50 | 0.52 | 0.49 | 0.70 |
| Cash Conversion Cycle | 207.25 | 200.18 | 239.75 | 182.67 |